Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAIC 2021 | Highlights from AAIC: Targeting the immune response to treat AD

Jacobo Mintzer • 5 Aug 2021
AAIC 2021
Alzheimer’s Disease Dementia

Jacobo E. Mintzer, MD, of the Medical University of South Carolina, discusses the emphasis on inflammation and the immune response in the treatment of Alzheimer’s disease (AD), seen at the 2021 Alzheimer’s Association International Conference (AAIC). He notes that several studies were presented looking at new potential targets for the treatment of AD, based on better management of the immune response. This interview took place during the Alzheimer’s Association International Conference (AAIC), 2021.

Disclosures

Prof. Mintzer reports the following disclosures:
AARP – Global Council on Brain Health, AARP – Staying Sharp, ACADIA, ACTC/ATRI, Alzheimer’s Association (local and national), BioPharma Connex, Cerevel Therapeutics, Genentech Pharmaceuticals, International Psychogeriatric Association, NeuroQuest, Praxis Pharmaceuticals, Recruitment Partners LLC, Technology Accelerator Company, Elder Court.

More from Jacobo Mintzer

Life’s End Benefits of cannaBidiol and tetrahYdrocannabinol (LiBBY) study
4:45
Life’s End Benefits of cannaBidiol and tetrahYdrocannabinol (LiBBY) study
Jacobo Mintzer • 13 Jul 2026
Phase III ADMET2 trial of methylphenidate for apathy in Alzheimer's Disease
7:14
Phase III ADMET2 trial of methylphenidate for apathy in Alzheimer's Disease
Jacobo Mintzer • 5 Aug 2021

Related Videos

A multimodal model to detect and stage Alzheimer's disease using MRI, acoustic signals, and genetics
10:28
A multimodal model to detect and stage Alzheimer's disease using MRI, acoustic signals, and genetics
Muhammad Umar Khan • 28 Aug 2026
Neuroprotective effects of aortic valve replacement: a propensity score-matched cohort study
3:25
Neuroprotective effects of aortic valve replacement: a propensity score-matched cohort study
Vikash Jaiswal • 26 Aug 2026
The Lewy Body Society's mission and impact
2:38
The Lewy Body Society's mission and impact
Jacqui Cannon • 5 Aug 2026
Neflamapimod receives ILAP designation in the UK for dementia with Lewy bodies
2:44
Neflamapimod receives ILAP designation in the UK for dementia with Lewy bodies
Jacqui Cannon • 5 Aug 2026

Choose your cookie settings

VJDementia uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJDementia is intended for healthcare professionals